Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Dexcom and Welldoc Expand Partnership for T2DM

Here is a brief preview of this blast: Dexcom and Welldoc announced "the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes," which is thought to mean the companies are transitioning from an integration/development focus to a commercial collaboration. According to the press release, the expanded partnership will combine real-time CGM and "AI-driven digital health coaching" to improve the management of T2DM. Below, FENIX provides thoughts on why the Dexcom/Welldoc collaboration makes sense as well as insight into the impending battle between AI and human coaching tools.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.